Department of Computer Science, Hunter College, The City University of New York, New York, United States of America.
Ph.D. Program in Computer Science, The City University of New York, New York, United States of America.
PLoS Comput Biol. 2021 Feb 12;17(2):e1008653. doi: 10.1371/journal.pcbi.1008653. eCollection 2021 Feb.
Drug combinations have demonstrated great potential in cancer treatments. They alleviate drug resistance and improve therapeutic efficacy. The fast-growing number of anti-cancer drugs has caused the experimental investigation of all drug combinations to become costly and time-consuming. Computational techniques can improve the efficiency of drug combination screening. Despite recent advances in applying machine learning to synergistic drug combination prediction, several challenges remain. First, the performance of existing methods is suboptimal. There is still much space for improvement. Second, biological knowledge has not been fully incorporated into the model. Finally, many models are lack interpretability, limiting their clinical applications. To address these challenges, we have developed a knowledge-enabled and self-attention transformer boosted deep learning model, TranSynergy, which improves the performance and interpretability of synergistic drug combination prediction. TranSynergy is designed so that the cellular effect of drug actions can be explicitly modeled through cell-line gene dependency, gene-gene interaction, and genome-wide drug-target interaction. A novel Shapley Additive Gene Set Enrichment Analysis (SA-GSEA) method has been developed to deconvolute genes that contribute to the synergistic drug combination and improve model interpretability. Extensive benchmark studies demonstrate that TranSynergy outperforms the state-of-the-art method, suggesting the potential of mechanism-driven machine learning. Novel pathways that are associated with the synergistic combinations are revealed and supported by experimental evidences. They may provide new insights into identifying biomarkers for precision medicine and discovering new anti-cancer therapies. Several new synergistic drug combinations have been predicted with high confidence for ovarian cancer which has few treatment options. The code is available at https://github.com/qiaoliuhub/drug_combination.
药物组合在癌症治疗中显示出巨大的潜力。它们缓解了药物耐药性,提高了治疗效果。抗癌药物数量的快速增长使得对所有药物组合的实验研究变得昂贵且耗时。计算技术可以提高药物组合筛选的效率。尽管机器学习在协同药物组合预测中的应用最近取得了进展,但仍存在一些挑战。首先,现有方法的性能并不理想,仍有很大的改进空间。其次,生物知识尚未充分纳入模型。最后,许多模型缺乏可解释性,限制了它们的临床应用。为了解决这些挑战,我们开发了一种知识增强和自注意力转换器增强的深度学习模型 TranSynergy,它提高了协同药物组合预测的性能和可解释性。TranSynergy 的设计使得通过细胞系基因依赖性、基因-基因相互作用和全基因组药物-靶标相互作用,可以明确建模药物作用的细胞效应。开发了一种新的 Shapley 加性基因集富集分析 (SA-GSEA) 方法来分解对协同药物组合有贡献的基因,从而提高模型的可解释性。广泛的基准研究表明,TranSynergy 优于最先进的方法,这表明基于机制的机器学习具有潜力。揭示了与协同组合相关的新途径,并得到了实验证据的支持。它们可能为识别精准医学的生物标志物和发现新的抗癌疗法提供新的见解。针对卵巢癌这种治疗选择较少的癌症,我们预测了几种具有高置信度的新协同药物组合。代码可在 https://github.com/qiaoliuhub/drug_combination 获得。